- Design
- Biomarker sub-study within a randomised lung-cancer screening trial (ITALUNG)
- Population
- 55 lung-cancer patients with pre-diagnostic blood and sputum samples
- Primary outcome
- Biomarker panel sensitivity for lung cancer in pre-diagnostic samples
- Effect
- 95% (20/21) near diagnosis; ~83% (5/6) within 3 years before diagnosis
The ITALUNG trial randomised over 3,100 high-risk smokers and ex-smokers aged 55–69 to low-dose CT screening, which reduced long-term lung-cancer and cardiovascular mortality, with a notable benefit in women. This analysis asked whether a molecular biomarker panel could catch cancers even earlier.
The panel — loss of heterozygosity and microsatellite instability plus circulating free DNA in blood and sputum — was positive in 20 of 21 cancers tested close to diagnosis (about 95%), and in five of six cancers using samples collected within three years before diagnosis (about 83%). It detected two-thirds of early, resectable cancers from samples up to 11 years before diagnosis.
The sensitivity in pre-diagnostic samples is striking, but these are very small numbers with wide confidence intervals, and the respective roles of CT and biomarkers are unsettled. This is research toward a future screening adjunct, not a test to deploy — and where even low-dose CT screening is not yet routine, as in India, it remains some distance from practice.
- A blood-and-sputum biomarker panel was positive in about 95% of cancers tested near diagnosis.
- It flagged most cancers from samples taken up to three years before diagnosis.
- Numbers were very small, with wide confidence intervals.
- Low-dose CT reduced lung-cancer and cardiovascular mortality in the parent ITALUNG trial.
Why it matters
It points to a possible future adjunct to CT screening, while underscoring how early such tools still are.
Don't overread it
Sensitivities rest on handfuls of cancers with very wide intervals, and the mortality benefit belongs to CT screening in the parent trial, not to the biomarker panel.
The statistics, in plain English
A 95% sensitivity from 20 of 21 cancers, or 83% from five of six, carries confidence intervals so wide they reach beyond 100%, so the true accuracy is far less certain than the point estimates look.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free